VALENCIA MARTINEZ, ANA BELEN
VALENCIA MARTINEZ, ANA BELEN
Medicina Sperimentale e Clinica
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
2014 VALENCIA MARTINEZ, ANA BELEN; Masala, Erico; Rossi, A.; Martino, A.; Sanna, A.; Buchi, Francesca; Canzian, F.; Cilloni, D.; Gaidano, V.; Voso, M. T.; Kosmider, O.; Fontenay, M.; Gozzini, A.; Bosi, Alberto; Santini, Valeria
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.
2014 Valencia A; Masala E; Rossi A; Martino A; Sanna A; Buchi F; Canzian F; Cilloni D; Gaidano V; Voso MT; Kosmider O; Fontenay M; Gozzini A; Bosi A; Santini V.
Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia
2017 Valencia-Martinez, Ana; Sanna, Alessandro; Masala, Erico; Contini, Elisa; Brogi, Alice; Gozzini, Antonella; Santini, Valeria
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.
2014 Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V.
Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures.
2018 Masala E, Valencia-Martinez A, Pillozzi S, Rondelli T, Brogi A, Sanna A, Gozzini A, Arcangeli A, Dello Sbarba P, Santini V
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine | 2014 | VALENCIA MARTINEZ, ANA BELEN; Masala, Erico; Rossi, A.; Martino, A.; Sanna, A.; Buchi, Francesca; Canzian, F.; Cilloni, D.; Gaidano, V.; Voso, M. T.; Kosmider, O.; Fontenay, M.; Gozzini, A.; Bosi, Alberto; Santini, Valeria | |
| Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. | 2014 | Valencia A; Masala E; Rossi A; Martino A; Sanna A; Buchi F; Canzian F; Cilloni D; Gaidano V; Voso MT; Kosmider O; Fontenay M; Gozzini A; Bosi A; Santini V. | |
| Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia | 2017 | Valencia-Martinez, Ana; Sanna, Alessandro; Masala, Erico; Contini, Elisa; Brogi, Alice; Gozzini, Antonella; Santini, Valeria | |
| Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. | 2014 | Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V. | |
| Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. | 2018 | Masala E, Valencia-Martinez A, Pillozzi S, Rondelli T, Brogi A, Sanna A, Gozzini A, Arcangeli A, Dello Sbarba P, Santini V |